• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

一名44岁女性使用瑞波西汀后出现显著体重减轻。

Profound weight loss associated with reboxetine use in a 44-year-old woman.

作者信息

Lu T Y-T, Kupa A, Easterbrook G, Mangoni A A

机构信息

Department of Clinical Pharmacology & Centre for Neuroscience, Flinders Medical Centre and Flinders University, Adelaide, Australia.

出版信息

Br J Clin Pharmacol. 2005 Aug;60(2):218-20. doi: 10.1111/j.1365-2125.2005.02407.x.

DOI:10.1111/j.1365-2125.2005.02407.x
PMID:16042676
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1884922/
Abstract

We report a case of significant weight loss experienced by a 44-year-old Caucasian woman treated with reboxetine. She was treated with this drug at 12 mg daily for a total duration of 11 months. During the corresponding period her body mass index (BMI) decreased from a baseline of 21.4 kg m(-2) to a low of 16.8 kg m(-2). Withdrawal of the drug led to a full recovery of her BMI. The strongest evidence linking reboxetine to this woman's weight loss laid in the fact that the re-introduction of the drug subsequently caused a similar negative impact in her BMI.

摘要

我们报告了一例44岁接受瑞波西汀治疗的白人女性出现显著体重减轻的病例。她接受该药物治疗，每日剂量为12毫克，总疗程为11个月。在相应时间段内，她的体重指数（BMI）从基线的21.4千克/米²降至最低的16.8千克/米²。停药后她的BMI完全恢复。将瑞波西汀与该女性体重减轻联系起来的最有力证据在于，随后再次使用该药物对她的BMI产生了类似的负面影响。

相似文献

1
Profound weight loss associated with reboxetine use in a 44-year-old woman.一名44岁女性使用瑞波西汀后出现显著体重减轻。
Br J Clin Pharmacol. 2005 Aug;60(2):218-20. doi: 10.1111/j.1365-2125.2005.02407.x.
2
Managing reboxetine-associated urinary hesitancy in a patient with major depressive disorder: a case study.治疗伴有重度抑郁症的患者中与瑞波西汀相关的排尿犹豫：一项病例研究。
Psychopharmacology (Berl). 2002 Feb;159(4):445-6. doi: 10.1007/s00213-001-0971-4. Epub 2001 Dec 20.
3
Reboxetine and hyponatremia.瑞波西汀与低钠血症
N Engl J Med. 2000 Jan 20;342(3):215-6. doi: 10.1056/NEJM200001203420315.
4
Depersonalization-derealization syndrome induced by reboxetine.瑞波西汀诱发的人格解体-现实解体综合征
Swiss Med Wkly. 2003 Jul 12;133(27-28):398-9. doi: 10.4414/smw.2003.10195.
5
Adjunctive zonisamide for weight loss in euthymic bipolar disorder patients: a pilot study.辅助使用唑尼沙胺治疗心境正常的双相情感障碍患者减肥：一项初步研究。
J Psychiatr Res. 2008 May;42(6):451-7. doi: 10.1016/j.jpsychires.2007.05.005. Epub 2007 Jul 12.
6
Monotherapy with reboxetine in amphetamine withdrawal syndrome.瑞波西汀单药治疗苯丙胺戒断综合征。
Prog Neuropsychopharmacol Biol Psychiatry. 2006 Sep 30;30(7):1353-5. doi: 10.1016/j.pnpbp.2006.03.008. Epub 2006 Apr 24.
7
Sleepwalking associated with reboxetine in a young female patient with major depression--a case report.一名患有重度抑郁症的年轻女性患者服用瑞波西汀后出现梦游——病例报告
Pharmacopsychiatry. 2004 Nov;37(6):307-8. doi: 10.1055/s-2004-832692.
8
Reboxetine-induced hypomania.瑞波西汀诱发的轻躁狂
J Clin Psychiatry. 2001 Aug;62(8):655-6. doi: 10.4088/jcp.v62n0813c.
9
Sexual dysfunction caused by reboxetine.瑞波西汀引起的性功能障碍。
Pharmacopsychiatry. 2002 Mar;35(2):77-8. doi: 10.1055/s-2002-25025.
10
Reboxetine induced erectile dysfunction and spontaneous ejaculation during defecation and micturition.瑞波西汀导致排便和排尿时勃起功能障碍及自发性射精。
Prog Neuropsychopharmacol Biol Psychiatry. 2007 Mar 30;31(2):548-50. doi: 10.1016/j.pnpbp.2006.10.006. Epub 2006 Nov 22.

引用本文的文献

1
Efficacy of adjunctive treatments added to olanzapine or clozapine for weight control in patients with schizophrenia: a systematic review and meta-analysis.奥氮平或氯氮平联合辅助治疗对精神分裂症患者体重控制的疗效：一项系统评价和荟萃分析。
ScientificWorldJournal. 2015;2015:970730. doi: 10.1155/2015/970730. Epub 2015 Jan 13.

本文引用的文献

1
Use of reboxetine in bulimia nervosa: a pilot study.
J Psychopharmacol. 2004 Sep;18(3):423-8. doi: 10.1177/026988110401800314.
2
Reboxetine: a norepinephrine selective reuptake pump inhibitor.瑞波西汀：一种去甲肾上腺素选择性再摄取泵抑制剂。
J Psychiatr Pract. 2004 Jan;10(1):57-63. doi: 10.1097/00131746-200401000-00006.
3
The pharmacology of human appetite expression.人类食欲表达的药理学。
Curr Drug Targets. 2004 Apr;5(3):221-40. doi: 10.2174/1389450043490541.
4
Metabolic drug interactions with new psychotropic agents.新型精神药物的代谢性药物相互作用。
Fundam Clin Pharmacol. 2003 Oct;17(5):517-38. doi: 10.1046/j.1472-8206.2003.00193.x.
5
Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: a double-blind, placebo-controlled study.瑞波西汀减轻精神分裂症患者奥氮平所致体重增加的双盲、安慰剂对照研究。
Am J Psychiatry. 2003 Feb;160(2):297-302. doi: 10.1176/appi.ajp.160.2.297.
6
Reboxetine in the treatment of bulimia nervosa: a report of seven cases.
Int Clin Psychopharmacol. 2000 Nov;15(6):351-6. doi: 10.1097/00004850-200015060-00006.
7
A method for estimating the probability of adverse drug reactions.一种估算药物不良反应概率的方法。
Clin Pharmacol Ther. 1981 Aug;30(2):239-45. doi: 10.1038/clpt.1981.154.